A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
R-Pharm
University of Southern California
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Massachusetts General Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Case Comprehensive Cancer Center